Business Overview: Travere Therapeutics, Inc. (NASDAQ: TVTX)

---

Executive Summary

Travere Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on rare kidney diseases. Its flagship product, FILSPARI (sparsentan), received full FDA approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of disease progression — the first non-immunosuppressive oral therapy of its kind for this indication.

Beyond FILSPARI, Travere markets Thiola/Thiola EC (tiopronin) for cystinuria and collects ongoing milestone payments from its 2023 sale of the Chenodal/Cholbam bile acid portfolio to Mirum Pharmaceuticals, giving the company both a growing specialty product and a legacy royalty income stream.

---

1. Core Business Model & How They Work

Travere runs a classic rare-disease specialty pharma model: a focused U.S. sales force targets a small number of specialist physicians treating low-prevalence, high-unmet-need kidney conditions, supported by patient-support services that help with access and adherence.

[ Rare Disease R&D ] ➡️ [ FDA Approval (Accelerated or Full) ] ➡️ [ Specialty Sales Force → Nephrologists/Urologists ] ➡️ [ Patient Support & Direct-to-Patient Pharmacy ] ➡️ [ Ex-U.S. Partner Royalties ]

Key Operational Drivers

1. Specialist-Targeted Commercial Model: FILSPARI is sold through a dedicated nephrology sales force rather than a broad primary-care footprint, reflecting the small, concentrated prescriber base typical of rare disease.
2. Global Partnering for Ex-U.S. Reach: CSL Vifor commercializes FILSPARI in Europe, Australia, New Zealand, and other licensed territories, while Chugai holds Japan, South Korea, and Taiwan rights (via its acquisition of Renalys) — letting Travere monetize international markets without building its own global commercial infrastructure.
3. Milestone & Royalty Income: Non-product income supplements the P&L, including a $40.0 million market access payment and $17.5 million regulatory milestone from CSL Vifor, a $25.0 million Mirum milestone recognized in 2025, and $10.2 million from the Renalys/Chugai transaction.
4. Royalty Obligations: Travere owes royalties of 15%–17% of sparsentan net sales to Ligand and BMS, and Thiola royalties to Mission equal to the greater of $2.1 million or 20% of net sales — meaningful off-the-top costs embedded in its revenue model.

---

2. Product Portfolio

---

3. Competitive Landscape

IgA Nephropathy

Competes against Novartis (atrasentan/Vanrafia, zigakibart, Fabhalta/iptacopan), Otsuka (sibeprenlimab/Voyxact), Vera Therapeutics (atacicept), Vertex (povetacicept), and Calliditas (Tarpeyo) — a crowded and rapidly intensifying field, with SGLT2 inhibitors also used as background therapy.

FSGS

Faces earlier-stage competitors including Dimerix (DMX-200), Boehringer Ingelheim (BI 764198), Apellis, and Vertex's APOL1-mediated disease program.

Cystinuria

Thiola's generic tiopronin competition is direct and ongoing; Advicenne's potassium-citrate microtablet is also in development as an alternative approach.

---

4. Strategic Strengths & Risks

Strengths

• First-mover commercial position in a historically underserved IgAN market, with FILSPARI's full approval providing a durability advantage over earlier accelerated-approval-only competitors.
• Global partner network (CSL Vifor, Chugai) extends FILSPARI's commercial reach without Travere bearing full international commercialization costs.
• Diversified pipeline beyond FILSPARI, including a potential FSGS label expansion and a distinct enzyme-replacement program (pegtibatinase) in a separate rare disease.
• Non-product milestone income from the Mirum and Chugai transactions reduces reliance on FILSPARI alone in the near term.

Risks

• Intensifying IgAN competition: a wave of new entrants (Novartis, Otsuka, Vera, Vertex) threatens to erode FILSPARI's first-mover advantage over the next several years.
• Clinical/regulatory uncertainty in FSGS: the pivotal DUPLEX study did not reach statistical significance on its two-year eGFR primary endpoint, so the FSGS filing rests on proteinuria-based evidence — a higher-risk regulatory path, reflected in the extended PDUFA date.
• Pegtibatinase manufacturing risk: enrollment in the pivotal HARMONY study was voluntarily paused in September 2024 over scale-up issues, delaying the program.
• Thiola erosion: generic competition continues to shrink the legacy cystinuria franchise.
• Patent gaps: certain commercial products lack full patent protection, and FILSPARI's European patent faces active opposition.
• Capital needs: the company may require substantial additional capital depending on how milestones and royalties materialize.

---

5. Financial Overview

---

6. Summary Conclusion

Travere Therapeutics has converted years of rare-kidney-disease R&D into a genuine commercial asset in FILSPARI, the first fully approved, non-immunosuppressive oral therapy for IgA nephropathy, supported by global partnerships that extend its reach without full international buildout costs. A potential FSGS label expansion and a separate pegtibatinase program in homocystinuria give the company more than one path to growth beyond its flagship indication.

The near-term risk is twofold: a rapidly crowding IgAN competitive field that could compress FILSPARI's growth runway faster than expected, and binary regulatory and clinical catalysts — the April 2026 FSGS PDUFA date and the restarted pegtibatinase pivotal trial — that will materially re-rate the stock in either direction depending on outcome.